Look for a New Injectable Buprenorphine for OUD

October 2023

Brixadi will join Sublocade as the second long-acting injectable buprenorphine for moderate to severe opioid use disorder (OUD).

Both are administered subcutaneously by a healthcare provider.

They’re generally reserved for when there’s concern about adherence, misuse, or diversion...or patients don’t want to take daily doses.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote